Waiting-list funding halted at second hospital over ‘potential financial irregularities'
Funding to help alleviate waiting lists has been suspended at a second hospital because of 'potential financial irregularities'.
The National Treatment Purchase Fund (NTPF) said it had suspended all insourcing work at the public hospital since April 11th and immediately informed the Department of Health and Health Service Executive (HSE).
Advertisement
The matter had been referred to the HSE's internal audit team.
'The board and executive of the NTPF take their responsibilities very seriously and will take whatever actions are necessary to ensure our spend with public hospitals is fully protected for the benefit of public patients,' NTPF chief executive Fiona Brady said.
'Any proven misuse of public money by public institutions will be treated with the gravity it deserves.'
The NTPF, which is a body that arranges external treatments for patients on public hospital waiting lists, has come under scrutiny in recent weeks.
Advertisement
It was reported in the Sunday Times that a consultant breached HSE guidelines by referring patients he was seeing in his public practice to his weekend private clinics, rather than securing earlier treatment for them by referring them to HSE colleagues.
The newspaper said the consultant was paid thousands of euro through the NTPF, and the details were uncovered by an internal investigation by Children's Health Ireland (CHI).
The NTPF said on Wednesday that following a meeting of its board, it would immediately recommence insourcing work with CHI after a review of its assurances.
But it said that the board and executive 'remain deeply concerned' that there had been a breach of its processes by another public body.
Advertisement
It said governance and oversight across its insourcing work with public hospitals – who until now have been responsible for this internal governance – would increase.
As well as notifying the Department of Health and HSE of its decision, the NTPF had also written to all public hospitals with whom it funds insourcing work to obtain further confirmation that all work is carried out in line with the NTPF's processes and procedures.
A deadline of Monday, June 16th, has been given for the completion of these replies.
'Insourcing work through the NTPF has delivered benefits to thousands of patients in recent years and has a demonstrable impact on waiting times and waiting-list numbers,' Ms Brady said.
Advertisement
'However, it is vital there is public trust and confidence around insourcing with public hospitals.
'It must be remembered that these public hospitals already have clear and established lines of reporting and accountability within the public system and clear obligations to comply with the terms of the signed memorandum of understanding in respect of NTPF-funded work.
'We will now work urgently with the Department of Health and HSE on any additional measures that may be needed to ensure that necessary controls of NTPF-funded initiatives are in place in the public hospitals.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
I was diagnosed with Alzheimer's after ‘overused' medical procedure caused my dementia
Sean Fischer's mother had been getting sicker for decades. She would ask the same question multiple times, be bedbound from migraines and unstable on her feet. The mystery behind her decades-long ailments was seemingly solved when she was diagnosed with Alzheimer's disease in June 2022. Sean said: 'We had spent countless hours fretting over what could be wrong, but not once did I think it could be early-onset Alzheimer's. That diagnosis belongs to other families, I thought. Not ours.' The Fischers met with renowned neurologists and prepared the then-61-year-old to participate in an Alzheimer's clinical trial for the drug varoglutamstat. Then came devastating news that meant Mrs Fischer wouldn't be eligible for the trial - she was suffering from a persistent leak of spinal fluid somewhere in her spinal system, but doctors couldn't pinpoint the source - and couldn't fix it. They believed it was likely a result of epidurals she'd received during childbirth - an injection in the back that numbs a person from their belly button to their thighs. It's a common pain relief option during childbirth and an estimated 61 percent of women who give birth receive an epidural. After suffering for more than a decade, doctors said a new procedure would allos them to inject dye into Mrs Fischer's spinal fluid to search for the leak - a small spot in the middle of her back. A few weeks after they sealed it, all of her symptoms went away and doctors said she didn't actually have Alzheimer's - the tiny spot in her back was actually the source of all her symptoms. Mrs Fischer's health battle began long before her Alzheimer's diagnosis. It started in spring 2001, when Sean said he received a call from his dad: Mom had pulled over on the highway, vomiting from a sudden, crushing headache. Her doctor called it a migraine, but months later she lost hearing in one ear and was diagnosed with Ménière's disease. She adjusted — avoiding movements that triggered vertigo, wearing a hearing aid in her forties, and taking daily meds for the headaches. Even as she quietly suffered, Sean wrote for The Free Press, she stayed steady for him and his brothers, never missing a soccer game, school musical, or packed lunch. In 2010, neurologists at Columbia University diagnosed her with a Chiari malformation, a structural defect where the brain is pushed through the opening at the base of the skull. They suspected the malformation was caused by a cerebrospinal fluid leak, sparked by her three epidurals from the births of each of her sons. Epidurals are extremely safe and are administered by inserting a needle in the space of the lower spine just outside the membrane that surrounds the spinal cord. It delivers anesthetic medication, which numbs the lower half of the body and blocks pain while allowing the patient to stay awake and alert. However, it can occasionally result in a leak if the needle punctures the thin, tough membrane surrounding the spinal cord containing the CSF, called the dura mater. When this happens, some of the fluid that cushions and protects the brain and spinal cord can leak out into surrounding tissues. It can only be patched up surgically. The leak had, over the years, led to a loss in cerebrospinal fluid volume, causing her brain to sink. This can lead to severe headaches, nausea and vomiting, hearing changes, memory problems, and double vision. 'I started high school in 2015, and around that time, I began to notice the quiet dislocation of my mom's mind,' Sean wrote for The Free Press. 'When we cooked dinner together, she would have trouble following recipes. She'd stare at her calendar for long stretches of time; making sense of it seemed to require more effort than usual. She started to repeat herself. 'By the time I left for college in Rhode Island, the phrase 'You already asked me that' had become a common refrain in the house I grew up in, but at first, we blamed her, telling her she needed to pay more attention.' She was seeing doctors for headaches, hearing, and anxiety, none of whom believed there could be a common origin. Her memory problems were worsening as well, which led to Mr and Mrs Fischer to to turn to NYU Langone Health's Center for Cognitive Neurology. 'My mom was tested extensively — and two months later came the diagnosis, with the finality of a punctuation mark. Alzheimer's. When it hit her that there was no cure, my mom was bedridden for three days,' Sean said. Hope came with the study. But then doctors called the Fischers and informed them that the CSF leak would not allow her to participate. Despair took over. But a few weeks later, Mrs Fischer's doctor called to tell them about recent medical innovations that would allow surgeons to find and fix the leak, allowing her to participate in the drug trial. Six months later, doctors inserted a probe through the femoral artery in Mrs Fischer's leg, fed it upward toward her spinal system, and sealed the leak. Sean said: 'Two weeks later, I visited home, and found Mom more alert than she had been in years. There was no absent look in her eyes. As the day went on, I waited for her to start fading—but she was still wide awake at 10 p.m. 'After three weeks, her vertigo was gone, and her physical therapist told her she didn't need treatment anymore, because she no longer had any balance problems. After four weeks, she told us she felt 20 years younger.' After six weeks, her problems with memory were gone entirely. 'And eventually, Mom's neurologist confirmed: She did not have Alzheimer's. The surgeons who fixed the leak were shocked. They had never seen a recovery like it,' Sean said. The family later learned that, a year before the procedure, Cedars-Sinai Medical Center had published a newsletter with the subtitle: 'Physicians Treating Dementia Should Look for Cerebrospinal Fluid Leak—A Treatable Cause of an Otherwise Incurable Condition.' The study followed 21 patients with headaches, severe fatigue, and diagnoses of Chiari malformation and dementia; nine were found to have a cerebrospinal fluid leak, and repairing it completely resolved their symptoms. In Sean's mother's case, countless specialists across multiple hospitals treated her symptoms in isolation, overlooking the root cause. But they chose not to place blame on any doctor or institution. It was the system that misdiagnosed her, and ultimately, the system that saved her. 'More than anything, we feel grateful that a scientific breakthrough came at just the right time; that the real cause of her suffering was found,' he said.
BBC News
5 hours ago
- BBC News
Cancer: World-first 'Trojan horse' therapy to be given on NHS
A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world can halt the blood cancer myeloma for nearly three times longer than current drug is an advanced form of chemotherapy that hits cancer with a bigger dose, while reducing Silvester, one of the first people to get it, says the therapy has been "life-changing" and he's now planning history-themed adventures. Myeloma – also known as multiple myeloma – affects part of the immune system called plasma cells. These are made in the spongey bone marrow in the centre of our who is 60 and from Sheffield, was diagnosed nearly two years ago after the cancer led to broken bones in his had a bone marrow transplant last year, but relapsed around Christmas. He has since been on the new therapy – called belantamab mafodotin – as part of an early access weeks he was in remission. Other treatments could have left him isolating in his bedroom for months, so Paul says the therapy "is absolutely life-changing" and was "creating that opportunity to enjoy" life. Visiting Hadrian's Wall is next on the agenda for history buff Paul; and he's looking forward to one of his daughters graduating later this year. "Most people say 'you look really really well'... I have a good normal life," he told the BBC. How does this therapy work? Paul's therapy - belantamab mafodotin – is a lethal chemotherapy drug that has been bound to an antibody, similar to the ones the body uses to fight infection. However, these antibodies have been designed to spot markings on the outside of plasma cells. So they travel to cancerous cells, stick to the surface and are then absorbed. Once inside they release their toxic payload, to kill the cancer. The therapy is named Trojan horse therapy after the siege of the city of Troy in Greek mythology, when a giant wooden horse was used to smuggle soldiers into the cannot be cured, but clinical trials last year showed the Trojan horse therapy halted the cancer for three years, compared to 13 months with current therapies. Prof Peter Johnson, the national clinical director for cancer at NHS England, said the difference was "life-changing".He told me: "This is a really important development for people with myeloma, because although we may not be able to cure the illness, giving them time free of the disease and free of the symptoms is really important."We've seen in the last few years that using antibodies to deliver chemotherapy drugs directly into cells can make a big difference for a variety of different types of cancer." Around 33,000 people are living with myeloma in the UK. The new drug will be used when the first-choice therapy fails, so around 1,500 patients a year could decision comes after a review by the National Institute of Health and Care Excellence (NICE) concluded the drug was cost-effective for NHS use. NICE recommendations are normally adopted in England, Wales and Northern Ireland while Scotland has its own process. The therapy is kinder than other cancer treatments, but is not free from side-effects. After a cancer cell has been destroyed, the remaining chemotherapy drug will leak into the body. This can cause dry eyes and blurred vision. 'These are very smart drugs' The technical name for these drugs is an therapy was developed by GSK in the UK with early research taking place in Stevenage and the first clinical trials in Martin Kaiser, team leader in myeloma molecular therapy at the Institute of Cancer Research, said these "are very smart drugs" and the difference in side effects compared to other drugs "is really remarkable".While myeloma is still considered an incurable cancer, Prof Kaiser says drugs like this are "an important step towards a functional cure" and he thinks long-term remission will go "above 50% in the next five years".Antibody drug conjugates are being developed for a range of cancers. The limitation is being able to design an antibody that can target the cancer alone. There is one that can target some types of breast cancer. Research is already taking place on stomach and bowel McKinlay, from the charity Myeloma UK, said the approval would "transform the lives of thousands" and it was "fantastic to see the UK at the forefront of myeloma treatment".Health Minister Karin Smyth, said: "This ground-breaking therapy puts the NHS at the forefront of cancer innovation."
Reuters
6 hours ago
- Reuters
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
June 12 (Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's (MRNA.O), opens new tab respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
